AGL 38.89 Increased By ▲ 0.33 (0.86%)
AIRLINK 218.65 Increased By ▲ 10.88 (5.24%)
BOP 10.40 Increased By ▲ 0.34 (3.38%)
CNERGY 7.05 Decreased By ▼ -0.03 (-0.42%)
DCL 10.02 Increased By ▲ 0.03 (0.3%)
DFML 41.09 Decreased By ▼ -0.05 (-0.12%)
DGKC 104.90 Increased By ▲ 1.44 (1.39%)
FCCL 36.85 Increased By ▲ 0.50 (1.38%)
FFBL 93.11 Increased By ▲ 1.52 (1.66%)
FFL 14.67 Increased By ▲ 0.07 (0.48%)
HUBC 140.95 Increased By ▲ 1.52 (1.09%)
HUMNL 14.30 Increased By ▲ 0.20 (1.42%)
KEL 6.00 Increased By ▲ 0.03 (0.5%)
KOSM 7.72 Decreased By ▼ -0.14 (-1.78%)
MLCF 47.80 Increased By ▲ 0.52 (1.1%)
NBP 70.80 Decreased By ▼ -2.96 (-4.01%)
OGDC 229.05 Increased By ▲ 6.39 (2.87%)
PAEL 39.10 Increased By ▲ 0.99 (2.6%)
PIBTL 9.32 Increased By ▲ 0.05 (0.54%)
PPL 210.00 Increased By ▲ 4.15 (2.02%)
PRL 40.98 Increased By ▲ 1.13 (2.84%)
PTC 26.98 Increased By ▲ 0.36 (1.35%)
SEARL 110.80 Increased By ▲ 0.56 (0.51%)
TELE 9.14 Decreased By ▼ -0.09 (-0.98%)
TOMCL 38.84 Increased By ▲ 0.63 (1.65%)
TPLP 14.09 Increased By ▲ 0.32 (2.32%)
TREET 26.50 Increased By ▲ 0.05 (0.19%)
TRG 60.60 Increased By ▲ 0.06 (0.1%)
UNITY 34.30 Increased By ▲ 0.16 (0.47%)
WTL 1.85 Decreased By ▼ -0.03 (-1.6%)
BR100 12,438 Increased By 139.3 (1.13%)
BR30 39,420 Increased By 542.4 (1.4%)
KSE100 115,334 Increased By 473.6 (0.41%)
KSE30 36,354 Increased By 158.2 (0.44%)

Searle Company Limited (Searle) has entered into a license agreement with China’s Mabwell Pharmaceuticals, under which Searle will manufacture, register, and market the Denosumab Biosimilars drugs in Pakistan.

Searle, which is principally engaged in the manufacture of pharmaceutical and other consumer products, shared the development in a notice to the Pakistan Stock Exchange (PSX) on Wednesday.

“Mabwell is pleased to partner with Searle Co Ltd to commercialize and localize Denosumab biosimilars in Pakistan,” said Dr Datao Liu, Co-founder, Chairman of the Board, and CEO of Mabwell in a statement.

Liu said Pakistan is an important country in China’s Belt and Road Initiative with a large market and ‘great demand’. “This partnership will benefit the patients in Pakistan by providing high quality affordable biological medicines,” he added.

Similar sentiments were expressed by Syed Nadeem Ahmed, Group Managing Director and CEO of Searle Company Limited.

“Partnership with Mabwell is an integral part of our strategy to develop further our biotechnology business in Pakistan,” said Nadeem Ahmed.

“The goal of this project is not only to bring Mabwell products to Pakistan, but also to establish cooperation with such an innovative company as Mabwell.

“This cooperation also represents an important milestone for Searle Co Ltd., and for our patients in Pakistan that will ensure the social benefit from an increased access to high-quality affordable medicines” he added.

Searle is one of the top pharmaceutical companies in Pakistan having eight state-of-the art manufacturing facilities and global presence in 18 countries.

Comments

Comments are closed.

Fazeel Siddiqui (Overseas Pakistani) Jul 12, 2023 06:54pm
Much need good news.
thumb_up Recommended (0)
USMAN GHANI Jul 13, 2023 03:01pm
Searle must enter in manufacturing or initially refilling . Biologicals. to start with blood derivatives and following up of Vaccines .
thumb_up Recommended (0)